The Diagnostic Utility of Novel Immunohistochemical Marker ERG in the Workup of Prostate Biopsies With “Atypical Glands Suspicious for Cancer”
暂无分享,去创建一个
M. Rubin | C. Magi-Galluzzi | Ming Zhou | S. Falzarano | Huiying He | Jianbo Li | Paula Carver | K. Smith
[1] S. Varambally,et al. Antibody-based detection of ERG rearrangement-positive prostate cancer. , 2010, Neoplasia.
[2] S-H Tan,et al. ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification , 2010, Prostate Cancer and Prostatic Diseases.
[3] C. Magi-Galluzzi,et al. Clinicopathological features of prostate cancers detected after an initial diagnosis of ‘atypical glands suspicious for cancer’ , 2010, Pathology.
[4] Markus Reischl,et al. ERG rearrangement is specific to prostate cancer and does not occur in any other common tumor , 2010, Modern Pathology.
[5] T. H. van der Kwast,et al. False-negative Prostate Needle Biopsies: Frequency, Histopathologic Features, and Follow-up , 2010, The American journal of surgical pathology.
[6] G. Haas,et al. Saturation biopsies for prostate cancer: current uses and future prospects , 2009, Nature Reviews Urology.
[7] C. Cooper,et al. ETS gene fusions in prostate cancer , 2009, Nature Reviews Urology.
[8] Arul M Chinnaiyan,et al. Prevalence of TMPRSS2-ERG Fusion Prostate Cancer among Men Undergoing Prostate Biopsy in the United States , 2009, Clinical Cancer Research.
[9] R. Abouassaly,et al. Risk of prostate cancer after diagnosis of atypical glands suspicious for carcinoma on saturation and traditional biopsies. , 2008, The Journal of urology.
[10] M. Loda,et al. Characterization of TMPRSS2-ERG Fusion High-Grade Prostatic Intraepithelial Neoplasia and Potential Clinical Implications , 2008, Clinical Cancer Research.
[11] S. Srivastava,et al. Mapping of TMPRSS2–ERG fusions in the context of multi-focal prostate cancer , 2008, Modern Pathology.
[12] R. Eeles,et al. Diversity of TMPRSS2-ERG fusion transcripts in the human prostate , 2007, Oncogene.
[13] C. Magi-Galluzzi,et al. The incidence of high‐grade prostatic intraepithelial neoplasia and atypical glands suspicious for carcinoma on first‐time saturation needle biopsy, and the subsequent risk of cancer , 2007, BJU international.
[14] M. Rubin,et al. TMPRSS2-ERG Fusion Prostate Cancer: An Early Molecular Event Associated With Invasion , 2006, The American journal of surgical pathology.
[15] V. Srikantan,et al. Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome , 2006, Oncogene.
[16] Inge Jonassen,et al. ERG upregulation and related ETS transcription factors in prostate cancer. , 2007, International journal of oncology.
[17] Ximing J. Yang,et al. A Working Group Classification of Focal Prostate Atrophy Lesions , 2006, The American journal of surgical pathology.
[18] R. Henrique,et al. TMPRSS2-ERG gene fusion causing ERG overexpression precedes chromosome copy number changes in prostate carcinomas and paired HGPIN lesions. , 2006, Neoplasia.
[19] J. Epstein,et al. Prostate needle biopsies containing prostatic intraepithelial neoplasia or atypical foci suspicious for carcinoma: implications for patient care. , 2006, The Journal of urology.
[20] J. Tchinda,et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. , 2006, Science.
[21] M. Rubin,et al. Basal Cell Cocktail (34&bgr;E12 + p63) Improves the Detection of Prostate Basal Cells , 2003, The American journal of surgical pathology.
[22] J. Epstein,et al. Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. , 1999, The American journal of pathology.
[23] D. Johnston,et al. Comparison of prostate biopsy schemes by computer simulation. , 1999, Urology.
[24] J. Cheville,et al. The focus of "atypical glands, suspicious for malignancy" in prostatic needle biopsy specimens: incidence, histologic features, and clinical follow-up of cases diagnosed in a community practice. , 1997, American journal of clinical pathology.